Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, shared a post on X about a paper by Hisato Kawakami et al. published in the Journal of Clinical Oncology:
“First-Line Nivo plus Low-Dose Ipi for MSI Advanced Gastric or Esophagogastric Junction Cancer
Phs II NO LIMIT
ORR 62.1%, 10.3% CR, DCR 79.3%
mPFS 13.8 mo
gr ≥3 TRAEs 37.9%
interesting translational program.”
Title: Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability–High Advanced Gastric or Esophagogastric Junction Cancer
Authors: Hisato Kawakami, Shigenori Kadowaki, Akitaka Makiyama, Masahiro Tsuda, Kenro Hirata, Naotoshi Sugimoto, Nozomu Machida, Hiroki Hara, Hidekazu Hirano, Taito Esaki, Yoshito Komatsu, Shuichi Hironaka, Yukari Kobayashi, Kazuhiro Kakimi, Yasutaka Chiba, Narikazu Boku, Ichinosuke Hyodo, Kei Muro.
You can read the Full Article in the Journal of Clinical Oncology.
More posts featuring Arndt Vogel.
